Osteopontin is a marker for cancer aggressiveness and patient survival

British Journal of Cancer

Volumn 103, Issue 6, 2010, Pages 861-869

  Weber, G F ^a,b   Lett, G S ^c   Haubein, N C ^c  

^a UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^b MetaMol Theranostics   (United States)

^c BioAnalytics Group   (United States)

Author keywords

grade; metastasis; stage; survival

Indexed keywords

OSTEOPONTIN; TUMOR MARKER;

HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; SURVIVAL;

HUMANS; NEOPLASMS; OSTEOPONTIN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77956442992     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605834     Document Type: Article

References (14)

1. Agresti A (2007) 2nd edn. An Introduction to Categorical Data Analysis. John Wiley and Sons, Inc: Hoboken, NJ
2. Alonso SR, Tracey L, Ortiz P, Pérez-Gómez B, Palacios J, Pollán M, Linares J, Serrano S, Sáez-Castillo AI, Sánchez L, Pajares R, Sánchez-Aguilera A, Artiga MJ, Piris MA, Rodŕ?guez-Peralto JL (2007) A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 67: 3450-3460
3. Ebert W, Muley T, Drings P (1996) Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Anticancer Res 16: 2161-2168
4. Hong F, Breitling R (2008) A comparison of meta-analysis methods for detecting differentially expressed genes in microarray experiments. Bioinformatics 24: 374-382
5. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL, Chory J (2006) RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 22: 2825-2827
6. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M (2006) Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 12: 442-446
7. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535
8. O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG (2005) An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 29: 1034-1041
9. Reinholz MM, Iturria SJ, Ingle JN, Roche PC (2002) Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR. Breast Cancer Res Treat 74: 255-269
10. Ribeiro-Silva A, Oliveira da Costa JP (2008) Osteopontin expression according to molecular profile of invasive breast cancer: a clinicopatho-logical and immunohistochemical study. Int J Biol Markers 23: 154-160
11. Rice ME, Harris GT (2005) Comparing effect sizes in follow-up studies: ROC Area, Cohen's d, and r. Law Hum Behav 29: 615-620
12. Ulmert D, O'Brien MF, Bjartell AS, Lilja H (2009) Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol 6: 384-391
13. Weber GF (2008) Molecular mechanisms of metastasis. Cancer Letters 270: 181-190
14. Weber GF (2010) Toward a molecular classification of cancer. Toxicology (in press)